Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr-/- mouse model

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kuba, Motoko ^a   Matsuzaka, Takashi ^a   Matsumori, Rie ^a   Saito, Ryo ^a   Kaga, Naoko ^c   Taka, Hikari ^c   Ikehata, Kei ^b   Okada, Naduki ^a   Kikuchi, Takuya ^a   Ohno, Hiroshi ^a   Han, Song Iee ^a   Takeuchi, Yoshinori ^a   Kobayashi, Kazuto ^a   Iwasaki, Hitoshi ^a   Yatoh, Shigeru ^a   Suzuki, Hiroaki ^a   Sone, Hirohito ^d   Yahagi, Naoya ^a   Arakawa, Yoji ^b   Fujimura, Tsutomu ^c   Nakagawa, Yoshimi ^a,b   Yamada, Nobuhiro ^a   Shimano, Hitoshi ^a,b   more..

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BILE ACID; CHOLESTEROL; FATTY ACID ELONGASES; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DEFICIENCY; DIET; DISEASE MODEL; DRUG EFFECTS; FATTY LIVER; GALLSTONE; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY;

ACETYLTRANSFERASES; ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; GALLSTONES; LIVER; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; RECEPTORS, LDL;

EID: 84949257809     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17604     Document Type: Article

References (49)

1. Lazo, M., Clark, J. M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver. Dis. 28, 339-350 (2008).
2. Argo, C. K., Caldwell, S. H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver. Dis. 13, 511-531 (2009).
3. Everhart, J. E., Bambha, K. M. Fatty liver: think globally. Hepatology 51, 1491-1493 (2010).
4. Cohen, J. C., Horton, J. D., Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523 (2011).
5. Day, C. P., James, O. F. Steatohepatitis: a tale of two "hits" Gastroenterology 114, 842-845 (1998).
6. Neuschwander-Tetri, B. A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774-788 (2010).
7. Tilg, H., Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
8. Sarwar, N. et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375, 1634-1639 (2010).
9. Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374 (2007).
10. Amaro, A. et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139, 149-153 (2010).
11. Musso, G. et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909-916 (2003).
12. Yasutake, K. et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 44, 471-477 (2009).
13. Mari, M. et al. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab. 4, 185-198 (2006).
14. Moon, Y. A., Shah, N. A., Mohapatra, S., Warrington, J. A., Horton, J. D. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J.Biol. Chem. 276, 45358-45366 (2001).
15. Matsuzaka, T. et al. Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J.Lipid Res. 43, 911-920 (2002).
16. Matsuzaka, T. et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13, 1193-1202 (2007).
17. Tang, N. et al. Ablation of Elovl6 protects pancreatic islets from high-fat diet-induced impairment of insulin secretion. Biochem. Biophys. Res. Commun. 450, 318-323 (2014).
18. Saito, R. et al. Macrophage Elovl6 deficiency ameliorates foam cell formation and reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31, 1973-1979 (2011).
19. Wouters, K. et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486 (2008).
20. Bieghs, V. et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PloS one 7, e30668 (2012).
21. Depner, C. M., Philbrick, K. A., Jump, D. B. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J.Nnutr.143, 315-323 (2013).
22. Ishibashi, S. et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirusmediated gene delivery. J.Clin.Invest. 92, 883-893 (1993).
23. Matsuzaka, T. et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 56, 2199-2208 (2012).
24. Allen, K., Jaeschke, H., Copple, B. L. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am.J. Pathol. 178, 175-186 (2011).
25. Zhang, Y. et al. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int. 32, 58-69 (2012).
26. Lake, A. D. et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol. Appl. Pharmacol. 268, 132-140 (2013).
27. Moschetta, A., VanBerge-Henegouwen, G. P., Portincasa, P., Palasciano, G., Van Erpecum, K. J. Cholesterol crystallization in model biles: effects of bile salt and phospholipid species composition. J. Lipid Res. 42, 1273-1281 (2001).
28. Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003).
29. Miyazaki, M., Kim, Y. C., Gray-Keller, M. P., Attie, A. D., Ntambi, J. M. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J.Biol.Chem.275, 30132-30138 (2000).
30. MacDonald, M. L. et al. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J. Lipid Res. 49, 217-229 (2008).
31. Watanabe, S., Tsuneyama, K. Cattle bile but not bear bile or pig bile induces lipid profile changes and fatty liver injury in mice: mediation by cholic acid. J. Toxicol. Sci. 37, 105-121 (2012).
32. Allard, J. P. et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a crosssectional study. J. Hepatol. 48, 300-307 (2008).
33. Wouters, K. et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 584, 1001-1005 (2010).
34. Zhao, L. et al. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J. Gastroenterol. Hepatol. 26, 875-883 (2011).
35. Chawla, A., Repa, J. J., Evans, R. M., Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
36. Crosignani, A. et al. Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease. Clin. Chim. Acta. 382, 82-88 (2007).
37. Beilke, L. D. et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab. Dispos. 37, 1035-1045 (2009).
38. Guillen, N. et al. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol. Genomics 37, 187-198 (2009).
39. Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D., Gonzalez, F. J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56, 118-129 (2012).
40. Cherrington, N. J., Slitt, A. L., Li, N., Klaassen, C. D. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32, 734-741 (2004).
41. Sturm, E. et al. Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. J. Hepatol. 42, 102-109 (2005).
42. Campion, S. N. et al. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G294-304 (2008).
43. Wang, D. Q., Carey, M. C. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic relevance and identification of a stable liquid crystalline state in cold, dilute and hydrophilic bile salt-containing systems. J. Lipid Res. 37, 606-630 (1996).
44. Usui, S., Hara, Y., Hosaki, S., Okazaki, M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J. Lipid Res. 43, 805-814 (2002).
45. Folch, J., Lees, M., Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957).
46. Ma, K. et al. Circadian dysregulation disrupts bile acid homeostasis. PloS one 4, e6843 (2009).
47. Bligh, E. G., Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).
48. Sekiya, M. et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38, 1529-1539 (2003).
49. Kumadaki, S. et al. Inhibition of ubiquitin ligase F-box and WD repeat domain-containing 7alpha (Fbw7alpha) causes hepatosteatosis through Kruppel-like factor 5 (KLF5)/peroxisome proliferator-activated receptor gamma2 (PPARgamma2) pathway but not SREBP-1c protein in mice. J. Biol. Chem. 286, 40835-40846 (2011).